Guest guest Posted February 22, 2003 Report Share Posted February 22, 2003 Abnormal glucose tolerance in cystic fibrosis: Why should patients be screened? -- Journal of Pediatrics http://www.pulmonologylinx.com/thearts.cfm?artid=519589 & specid=14 Conclusion: Whereas the optimal treatment of their insulin deficient state is debatable and awaits the completion of ongoing studies, these high-risk patients warrant close observation and aggressive treatment of their pulmonary status by the CF team... ______________________________________________ Glucose intolerance in children with cystic fibrosis -- Journal of Pediatrics http://www.pulmonologylinx.com/thearts.cfm?artid=519596 & specid=14 Conclusion: Screening of pancreatic-insufficient, adolescent patients with CF identified more with abnormal oral glucose tolerance than was suspected clinically and is recommended as a routine practice. HbA1C was not useful in screening for CF-related glucose intolerance... ______________________________________________ Health values of adolescents with cystic fibrosis -- Journal of Pediatrics http://www.pulmonologylinx.com/thearts.cfm?artid=519597 & specid=14 Conclusion: Direct utility assessment in adolescents with CF is feasible. Their TTO and SG utilities are generally high, indicating that they are willing to trade very little of their life expectancy or take more than a small risk of death to obtain perfect health. Their self-rated health perceptions are related to their health values, but, as in adult populations, only moderately so, indicating that health values are highly individualistic. Therefore, health values should be ascertained directly from adolescents... ______________________________________________ Molecular Species Compositions of Lung and Pancreas Phospholipids in the cftrtm1HGU/tm1HGU Cystic Fibrosis Mouse -- Pediatric Research http://www.pulmonologylinx.com/thearts.cfm?artid=519736 & specid=14 Conclusion: These results demonstrate the variability of membrane phospholipid compositions in different mouse models of CF and suggest that in cftrtm1HGU/tm1HGU mice, the apparent deficiency was of 20:4n-6- rather than of 22:6n-3–containing phospholipid species. They highlight a need for detailed phospholipid molecular species analysis of cells expressing mutant CFTR from children with CF before the therapeutic effects of administering high doses of 22:6n-3–containing oils to children with CF can be fully evaluated... Becki YOUR FAVORITE LilGooberGirl YOUNGLUNG EMAIL SUPPORT LIST www.topica.com/lists/younglung Pediatric Interstitial Lung Disease Society http://groups.yahoo.com/group/InterstitialLung_Kids/ Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.